Prescribing Information for:KliovanceKliofemNovofemTrisequensVagifem

Prescribing Information for:KliovanceKliofem

NovofemTrisequensVagifem

Effectively treats the root cause of vaginal atrophy1

Effective1,2 convenient and clean3,4

Recommend Vagifem® 10µg:
• Most prescribed local treatment for vaginal atrophy in England5
• Significant improvement in vaginal health versus placebo from 2 weeks2
• Precise, user-friendly dosing delivered where it is needed1,2,6

Vaginal oestrogen is recommended by NICE for the treatment of urogenital atrophy7

References:
1. Vagifem® 10μg Summary of Product Characteristics. 2. Simon J, et al. Obstet Gynecol 2008; 112:1053-1060. 3. Rioux JE et al. Menopause 2000; 7(3):156-161. 4. Dugal R et al. Acta Obstet Gynecol Scand 2000; 79:293-297. 5. NHS Digital. Prescription Cost Analysis 2018 – Tables, 2019. Available at: https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018 [accessed December 2019]. 6. Minkin MJ, et al. Int J Women’s Health 2013;6:281–288. 7. NICE Guideline NG23 Menopause: diagnosis and management, November 2015.

This is a Novo Nordisk® website intended for UK healthcare professionals

Date of preparation: July 2020  UK20VG00009   Privacy Policy   Contact us

This is a Novo Nordisk® website intended for healthcare professionals

Date of preparation: July 2020
UK20VG00009
Privacy Policy   Contact us